Assess whether to resubmit, meet, or pause the program (c7e55b)

SITUATION Pediatric-plan strategist must settle whether to resubmit, meet, or pause the program because a CMO 483 that maps to the NDA CMC module hit a company with a CMC site change mid-review. The evidence on hand is phase-3 protocol with endpoint-sensitivity issues; name the Pharma & Life Sciences option that file actually supports.

DECISION Pediatric-plan strategist in a company with a CMC site change mid-review must choose To resubmit, meet, / Pause the program using phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; phase-3 protocol with endpoint-sensitivity issues already has the discriminator after a CMO 483 that maps to the NDA CMC module. 2. Keep Pause the program in force until phase-3 protocol with endpoint-sensitivity issues is completed after a CMO 483 that maps to the NDA CMC module for pediatric-plan strategist. 3. Treat phase-3 protocol with endpoint-sensitivity issues as To resubmit, meet, because both readings appear after a CMO 483 that maps to the NDA CMC module. 4. Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the decision to resubmit, meet, or turns on in phase-3 protocol with endpoint-sensitivity issues.

ANALYSIS REQUIRED 1. Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim pediatric-plan strategist would keep. 2. Map FDA-response timing and owner in a company with a CMC site change mid-review. 3. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to resubmit, meet, or for pediatric-plan strategist.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for pediatric-plan strategist - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - Regulatory or exam hook CMC and Development Pathways would cite - CMC and Development Pathways finding in phase-3 protocol with endpoint-sensitivity issues that a second reviewer can re-perform